The Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
The Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180. doi: 10.1016/j.chembiol.2017.08.028.
Metabolic reprogramming contributes to tumor development and introduces metabolic liabilities that can be exploited to treat cancer. Chemotherapies targeting metabolism have been effective cancer treatments for decades, and the success of these therapies demonstrates that a therapeutic window exists to target malignant metabolism. New insights into the differential metabolic dependencies of tumors have provided novel therapeutic strategies to exploit altered metabolism, some of which are being evaluated in preclinical models or clinical trials. Here, we review our current understanding of cancer metabolism and discuss how this might guide treatments targeting the metabolic requirements of tumor cells.
代谢重编程有助于肿瘤的发生发展，并产生代谢缺陷，这些缺陷可被用于治疗癌症。靶向代谢的化疗药物已成功应用于癌症治疗数十年，这些疗法的成功证明了存在针对恶性代谢的治疗窗口。对肿瘤不同代谢依赖性的新认识为利用改变的代谢提供了新的治疗策略，其中一些策略正在临床前模型或临床试验中进行评估。在这里，我们综述了我们目前对癌症代谢的理解，并讨论了这如何指导针对肿瘤细胞代谢需求的治疗方法。
